NCI researchers: cancer treatments costly to compare

In an Zytiga abiraterone acetate from Johnson & Johnson (NYSE:JNJ) for a single non-inferiority trial comparing Zytiga with the generic ketoconazole could be almost $70 million. The researchers identified ketoconazole as a logical comparator because the drug has a similar mechanism of action to Zytiga and was used off-label for prostate cancer prior to Zytiga's approval. Both drugs inhibit cytochrome P450 17 alpha-hydroxylase/C17, 20 lyase (CYP17). ...